Dexfenfluramine 4635792 215570619 2008-05-28T20:00:58Z ChemNerd 2246483 Removed category "Phenethylamines"; Quick-adding category "Amphetamines" (using [[WP:HOTCAT|HotCat]]) {{drugbox | IUPAC_name = ''N''-Ethyl-1-[3-(trifluoromethyl)phenyl]-propan-2-amine | image = Dexfenfluramine.png | CAS_number = 3239-44-9 | ATC_prefix = A08 | ATC_suffix = AA04 | ATC_supplemental = | PubChem = 3337 | DrugBank = APRD00648 | C=12 | H=16 | F=3 | N=1 | molecular_weight = 231.257 g/mol | bioavailability = | protein_bound = 36% | metabolism = | elimination_half-life = 17-20 hours | pregnancy_category = | legal_US = Schedule IV | legal_status = Withdrawn from market | routes_of_administration = }} <!-- Deleted image removed: [[Image:ReduxAd.png|thumb|300px|left|A direct-to-physician advertisement for Redux.]] --> '''Dexfenfluramine''', also marketed under the name '''Redux''', is a serotoninergic [[anorectic]] drug. It was for some years in the mid-1990s approved by the United States [[Food and Drug Administration]] for the purposes of [[weight loss]]. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by [[sibutramine]], which is a safer alternative to both dexfenfluramine and [[fenfluramine]]. The drug was manufactured by [[Interneuron Pharmaceuticals]] and marketed by [[Wyeth-Ayerst Laboratories]]. It is the [[enantiomer]] of [[levofenfluramine]]. ==See also== *[[Fen-phen]] ==References== *[http://www.fda.gov/cder/news/phen/fenphenpr81597.htm ''FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)''] [[Category:Withdrawn drugs]] [[Category:Serotonin receptor agonists]] [[Category:Amphetamines]] {{pharma-stub}} {{Antiobesity preparations}} [[de:Dexfenfluramin]]